基本信息:
- 专利标题： Substituted bicyclic compounds as farnesoid x receptor modulators
- 申请号：IL28557021 申请日：2021-08-12
- 公开(公告)号：IL285570D0 公开(公告)日：2021-09-30
- 发明人： WACKER DEAN A , NARA SUSHEEL JETHANAND , CHERUKU SRINIVAS , SARKUNAM KANDHASAMY , JAIPURI FIROZ ALI , NARAYAN RISHIKESH , BANDREDDY SUBBA REDDY , JOGI SRINIVAS
- 申请人： SQUIBB BRISTOL MYERS CO , WACKER DEAN A , NARA SUSHEEL JETHANAND , CHERUKU SRINIVAS , SARKUNAM KANDHASAMY , JAIPURI FIROZ ALI , NARAYAN RISHIKESH , BANDREDDY SUBBA REDDY , JOGI SRINIVAS
- 专利权人： SQUIBB BRISTOL MYERS CO,WACKER DEAN A,NARA SUSHEEL JETHANAND,CHERUKU SRINIVAS,SARKUNAM KANDHASAMY,JAIPURI FIROZ ALI,NARAYAN RISHIKESH,BANDREDDY SUBBA REDDY,JOGI SRINIVAS
- 当前专利权人： SQUIBB BRISTOL MYERS CO,WACKER DEAN A,NARA SUSHEEL JETHANAND,CHERUKU SRINIVAS,SARKUNAM KANDHASAMY,JAIPURI FIROZ ALI,NARAYAN RISHIKESH,BANDREDDY SUBBA REDDY,JOGI SRINIVAS
- 优先权： US201962806042 2019-02-15
摘要：
Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.